{"id":"remd-477","_chembl":{"chemblId":"CHEMBL4298213","moleculeType":"Antibody"},"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"The specific molecular target and mechanism of action for REMD-477 have not been publicly disclosed in detail. Based on the company's focus, it likely modulates pathways related to metabolism and energy regulation.","oneSentence":"REMD-477 is believed to target metabolic pathways involved in energy balance and glucose homeostasis."},"_scrapedAt":"2026-03-28T03:45:05.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123329,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"semaglutide","brand":"Wegovy","company":"Novo Nordisk","rationale":"GLP-1 receptor agonist approved for obesity and weight management"},{"name":"tirzepatide","brand":"Zepbound","company":"Eli Lilly","rationale":"Dual GIP/GLP-1 receptor agonist for obesity and diabetes"}],"description":"REMD-477 is an investigational biologic therapy developed by REMD Biotherapeutics for metabolic disorders. The drug was evaluated in Phase 2 clinical trials for obesity and related metabolic conditions, though development status remains uncertain.","indications":{"approved":[{"status":"investigational","condition":"Obesity","patientPopulation":"Adult"},{"status":"investigational","condition":"Type 2 Diabetes Mellitus","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT07212868","phase":"PHASE1","title":"The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02-25","conditions":"Non-Diabetic","enrollment":150},{"nctId":"NCT04779645","phase":"PHASE2","title":"Effects of GRA in Patients With Type 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-07-31","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT05093517","phase":"EARLY_PHASE1","title":"Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-11-10","conditions":"Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity","enrollment":4},{"nctId":"NCT03117998","phase":"PHASE2","title":"Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"REMD Biotherapeutics, Inc.","startDate":"2017-09-19","conditions":"Type1 Diabetes Mellitus","enrollment":154},{"nctId":"NCT04545411","phase":"PHASE1, PHASE2","title":"Combination GRA and SGLT-2i Treatment in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-02-22","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT04330625","phase":"PHASE1","title":"Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)","status":"TERMINATED","sponsor":"Duke University","startDate":"2020-11-13","conditions":"Hyperglycemia Drug Induced","enrollment":1},{"nctId":"NCT03919617","phase":"PHASE1, PHASE2","title":"Metabolic Pathways of GRA in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-07-01","conditions":"Type 1 Diabetes Mellitus","enrollment":4},{"nctId":"NCT04253223","phase":"PHASE1","title":"A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib","status":"TERMINATED","sponsor":"Duke University","startDate":"2020-04-07","conditions":"Hyperglycemia Drug Induced","enrollment":1},{"nctId":"NCT02455011","phase":"PHASE1, PHASE2","title":"Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"REMD Biotherapeutics, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus, Diabetes","enrollment":75},{"nctId":"NCT02715193","phase":"PHASE1","title":"Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"REMD Biotherapeutics, Inc.","startDate":"2016-03","conditions":"Type 1 Diabetes Mellitus, Diabetes","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Volagidemab"],"phase":"phase_2","status":"active","brandName":"REMD-477","genericName":"REMD-477","companyName":"REMD Biotherapeutics, Inc.","companyId":"remd-biotherapeutics-inc","firstApprovalDate":"","aiSummary":"REMD-477 is an antibody that inhibits the glucagon receptor. It is being studied in clinical trials for conditions such as Type 1 Diabetes Mellitus and Hyperglycemia Drug Induced.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":7,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}